Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 6,680 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Bipolar I Disorder, Schizophrenia
Interventions: OLZ/SAM; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Dothan, Alabama • Little Rock, Arkansas • Stanford, California + 12 more

Conditions: Venous Vascular Closure, Electrophysiology Study
Interventions: MYNX CONTROLTM VENOUS Vascular Closure Device; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: Not listed
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more

Conditions: Stress, Psychological, Stress, Physiological, Anxiety, Pain Perception
Interventions: Use of Virtual Reality App; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pemphigus Vulgaris
Interventions: DSG3-CAART, CABA-201; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 13
States / cities: Redwood City, California • Sacramento, California • New Haven, Connecticut + 9 more

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: PTR-01; Drug
Lead sponsor: Phoenix Tissue Repair, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Redwood City, California • Aurora, Colorado

Conditions: Choroidal Melanoma, Indeterminate Lesions of Eye
Interventions: Not listed
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 13 more

Conditions: Narcolepsy Type 1
Interventions: TAK-861, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 21
States / cities: Birmingham, Alabama • Redwood City, California • Santa Ana, California + 18 more

Conditions: Myelodysplastic Syndrome
Interventions: eltrombopag olamine, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 24
States / cities: Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more

Conditions: Nearsightedness, Astigmatism
Interventions: LASIK; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: XL647; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Gilroy, California • Sacramento, California • Stanford, California + 7 more

Conditions: COVID, SARS-CoV2 Infection, Covid19
Interventions: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo; Biological · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 16
States / cities: Tucson, Arizona • Mather, California • Palo Alto, California + 13 more

Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Gastroparesis
Interventions: SmartPill Monitoring System; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 11
States / cities: Palo Alto, California • Largo, Florida • Miami, Florida + 8 more

Conditions: Prostate Cancer
Interventions: Artificial urinary sphincter, InVance Sling, AdVance Sling, Virtue Sling, Contigen; Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sedentary Lifestyle, Risk of Disability, Aging
Interventions: Physical Activity, Successful Aging; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 70 Years to 89 Years
Enrollment: 1,635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Gainesville, Florida + 5 more

Conditions: Graft vs Host Disease
Interventions: Visilizumab; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 7
States / cities: Duarte, California • Stanford, California • St Louis, Missouri + 4 more

Conditions: Endoscopy, Colonoscopy
Interventions: 5% inhaled nitrous oxide, 50% inhaled nitrous oxide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1655
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more

Conditions: Neuroblastoma
Interventions: hu14.18-Interleukin-2 fusion protein; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Membranous Nephropathy, Nephrotic Syndrome
Interventions: Belimumab, Placebo for Belimumab, Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Placebo, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 15 more

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: bortezomib, lenalidomide, dexamethasone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 275
States / cities: Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more

Conditions: Bipolar Disorder, Mental Health
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo, Zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more

Search by objective public record fields.

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

Mobilization and Outcomes After Venous Closure

Stress Inoculation Through Virtual Reality in the Pediatric Electrophysiology Laboratory

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

A Study of TAK-861 in Participants With Narcolepsy Type 1

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

High Resolution Wavefront-guided vs. Wavefront Optimized LASIK

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis

Male Stress Urinary Incontinence and Sexual Health

The LIFE Study - Lifestyle Interventions and Independence for Elders

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Can Nitrous Oxide (Laughing Gas) be Used as a Sedative for GI Endoscopy Procedures?

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Belimumab With Rituximab for Primary Membranous Nephropathy

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Reproductive Function and Mood in Women With Bipolar Disorder

Atrasentan in Patients With IgA Nephropathy